Abstracts tagged "radiography and rheumatoid arthritis (RA)"

Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir*³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
Abstract Number: 2973 • 2014 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score As a Predictor of Radiographic Progression in a Registry of Patients with Rheumatoid Arthritis
Eric H. Sasso¹, George Wu², CC Hwang², Michael E. Weinblatt³, Nancy A. Shadick⁴, Claire Alexander⁵ and Oscar Segurado¹, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ³Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose This study evaluated the association between baseline disease activity, as assessed with the multi-biomarker disease activity (MBDA) blood test, CRP or clinical measures, and…
Abstract Number: 2925 • 2014 ACR/ARHP Annual Meeting
Serum MMP-3 Predicts a Subgroup with No Radiographic Progression in Rheumatoid Arthritis Patients with Low-Dose Methotrexate (MTX) Monotherapy
Kazuko Shiozawa¹, Takashi Yamane², Miki Murata¹, Chihiro Tanaka¹, Noriaki Yo², Ryosuke Yoshihara¹, Yasushi Tanaka¹, Ken Tsumiyama³ and Shunichi Shiozawa⁴, ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Kohnan Kakogawa Hospital, Kakogawa, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Studies have shown that treating rheumatoid patients with methotrexate (MTX) monotherapy initially and later providing an option to step up to combination therapy produces…
Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…
Abstract Number: 2914 • 2014 ACR/ARHP Annual Meeting
The Clinical and Radiographic Course of Early Undifferentiated Arthritis Under Treatment Is Not Dependent on the Amount of Erosions at Diagnosis. Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Toni Kaegi², Sarah Haile³ and Johannes von Kempis⁴, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland, ⁴Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose To analyse whether early arthritis patients who do not fulfil the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) have a different course of…
Abstract Number: 2387 • 2014 ACR/ARHP Annual Meeting
Relation Between Disease Activity Indices and Their Individual Components and Radiographic Progression in Rheumatoid Arthritis: A Systematic Literature Review
Victoria Navarro-Compán¹, Ana Maria Gherghe², Josef Smolen³, Daniel Aletaha⁴, Robert B. M. Landewé^5,6 and Désirée van der Heijde⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶Atrium Medical Center, Heerlen, Netherlands, ⁷Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Background/Purpose: Composite indices and single items are available to monitor disease activity in rheumatoid arthritis (RA). Their relation to radiographic progression is an important aspect…
Abstract Number: 2131 • 2014 ACR/ARHP Annual Meeting
the Impact of Patient-Reported Flares on Radiographic Progression in Rheumatoid Arthritis Patients with Low-Disease Activity: Secondary Analyses from a Randomized Trial
Dorota Kuettel¹, Jette Primdahl^2,3,4,5, Lykke Midtbøll Ørnbjerg⁶, Hans Christian Horn⁷, Robin Christensen⁸ and Kim Hørslev-Petersen⁹, ¹Rheumatological, King Christian X's Hospital for Rheumatic Diseases, Graasten, Denmark, ²Rheumatology, King Christian X's Hospital for Rheumatic Diseases, Graasten, Denmark, ³Institute for Regional Health Research, University of Southern Denmark, Graasten, Denmark, ⁴Hospital of Southern Jutland, Soenderborg, Denmark, ⁵Danbio Registry, Glostrup, Denmark, ⁶Copenhagen Center for Arthritis Reasearch, Center for Rheumatology and Spine diseases, Glostrup Hospital, Copenhagen, Denmark, ⁷Internal Medicine/Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Rheumatology, MSU, The Parker Institute, Copenhagen University Hospital, Frederiksberg, Denmark, ⁹Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark
Background/Purpose Flares, potentially disabling and disease worsening even when a patient is in low disease activity, are common features in patients with rheumatoid arthritis (RA)…
Abstract Number: 2137 • 2014 ACR/ARHP Annual Meeting
Linear Extrapolation of Missing Radiographic Progression Scores Does Not Spuriously overestimate overall Radiographic Progression in Rheumatoid Arthritis
Iris Markusse¹, Robert Landewé^2,3, Meilien Ho⁴, Martin Jenkins⁴ and Desiree van der Heijde⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Atrium Medical Center, Heerlen, Netherlands, ⁴AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose : Linear Extrapolation (LE) is a frequently applied method to impute missing radiographic data in trials. However, there is frequent critique that LE overestimates…
Abstract Number: 1890 • 2014 ACR/ARHP Annual Meeting
Consistent Inhibition of Bone Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis
Naoki Ishiguro¹, Yoshiya Tanaka², Hisashi Yamanaka³, Toshiyuki Yoneda⁴, Takeshi Ohira⁵, Naoki Okubo⁶, Harry K. Genant⁷, Desiree van der Heijde⁸ and Tsutomu Takeuchi⁹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Daiich Sankyo Co. Ltd, Tokyo, Japan, ⁶1-2-58, Hiromachi, Daiichi Sankyo Co. Ltd, Tokyo, Japan, ⁷University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL, inhibits osteoclast-induced bone resorption by preventing the binding of RANKL…
Abstract Number: 1474 • 2014 ACR/ARHP Annual Meeting
Anti-Peptidyl Arginine Deiminase 4 Antibodies in African-Americans with Rheumatoid Arthritis and Radiographic Scores
Iris Navarro-Millan¹, Andrew Westfall², Erika Darrah^3,4, Antony Rosen⁵, Ted R. Mikuls⁶, Richard Reynolds², Maria I. Danila⁷, Jeffrey R. Curtis² and S. Louis Bridges Jr.^2,8, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, The Johns Hopkins University, Baltimore, MD, ⁴5200 Eastern Ave MFL Bldg Cntr, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The presence of serum autoantibodies to peptidyl arginine deiminase 4 (PAD4) have been associated with erosive rheumatoid arthritis (RA) in populations that were composed…
Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Boulos Haraoui¹, J. Carter Thorne², Edward C. Keystone³, Melanie Poulin-Costello⁴, Eric Trottier⁵, Andrew Vieira⁶ and Janet E. Pope⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Medical Communications, Amgen Canada, Mississauga, ON, Canada, ⁶Amgen Canada Inc., Mississauga, ON, Canada, ⁷St Joseph Health Care, London, ON, Canada
Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
Abstract Number: 1304 • 2013 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Suzanne M. Verstappen¹, Kimme L. Hyrich², Tarnya Marshall³, Anne Barton^4,5, René E.M. Toes⁶, Leendert A. Trouw⁶ and Deborah P. Symmons^4,7, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Autoantibodies against carbamylated proteins (anti-CarP) have been associated with more severe radiological damage in patients with rheumatoid arthritis (RA), including in a small subgroup…
Abstract Number: 1305 • 2013 ACR/ARHP Annual Meeting
Clinical Joint Involvement Is Decisive For Radiographic Progression
Miriam Gärtner¹, Farideh Alasti², Gabriela Supp¹, Josef S. Smolen³ and Daniel Aletaha¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Today’s therapeutic targets in rheumatoid arthritis (RA) are remission or low disease activity, but it was shown that joint damage may continue to progress…
Abstract Number: 1310 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima¹, Yuichi Takahashi⁸, Seiyo Honda⁹, Yoshiro Horai², Tomohiro Koga¹⁰, Mami Tamai¹¹, Kiyoshi Aoyagi¹², Ryu Watanabe⁵, Hiroshi Okuno¹³ and Katsumi Eguchi¹⁴, ¹Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Yu Family Clinic, Sendai, Japan, ⁹Kurume University School of Medicene, Kurume, Japan, ¹⁰Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ¹²Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹³Tohoku University Hospital, Sendai, Japan, ¹⁴Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). However, there has been few epidemiological report…
Abstract Number: 812 • 2013 ACR/ARHP Annual Meeting
Alveolar Bone Loss Is Associated With Disease Activity and ACPA Expression In Rheumatoid Arthritis
Ted R. Mikuls¹, Jeffrey Payne², Fang Yu³, Geoffrey M. Thiele⁴, Shawneen Gonzalez², Jeffrey Markt⁵, Jeremy Sokolove⁶, William H. Robinson⁷, Richard J. Reynolds⁸, Grant W. Cannon⁹, David McGowan¹⁰, Gail S. Kerr¹¹, Robert Redman¹², Andreas M. Reimold¹³, Garth Griffiths¹⁴, Mark Beatty², Marian Schmid², Paul Johnson², Debra Bergman¹⁵, Bartlett C. Hamilton III¹⁶, Alan R. Erickson¹ and James R. O'Dell¹⁷, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Int Med/Sec of Rheum/Immun, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Otol-Head and Neck Surgery, University of Nebraska Medical Center, Omaha, NE, ⁶Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ¹⁰Dentistry, George E. Wahlen VA Medical Center, Salt Lake City, UT, ¹¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ¹²Dentistry, Washington DC VA, Georgetown and Howard University, Washington, DC, ¹³Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁴Dentistry, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁵Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹⁶University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, NE, ¹⁷Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Periodontitis (PD) has been implicated in rheumatoid arthritis (RA) pathogenesis including the expression of anti-citrullinated protein antibody (ACPA). ACPA, in turn, have been shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].